Stilbenoid gaylussacin modulates particulate matter-induced chromatin remodeling in macrophages to suppress chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) affects millions worldwide and is a leading cause of mortality, characterized by conditions like chronic bronchitis and emphysema.¹ While current treatments can ease symptoms, they offer limited impact on the disease’s progression.²

The Role of Inflammation and Macrophages

Cigarette smoke is a primary risk factor for COPD, but exposure to airborne particulate matter (PM) also contributes and can even accelerate the disease. Researchers have found that dysregulated macrophages – a type of immune cell – play a key role in COPD by triggering inflammation and tissue destruction through the release of various substances.¹

Did You Know? Resveratrol, a compound found in grapes and other plants, has previously been shown to reverse some of the damaging effects of PM exposure in laboratory settings.³

Uncovering the CK2/CTCF Pathway

Recent research has focused on understanding the mechanisms that drive this macrophage dysfunction. Scientists discovered that exposure to PM leads to increased activity of a protein called CTCF, which then alters gene expression in macrophages. This process appears to be regulated by another protein, CK2. Specifically, PM exposure induced CK2 nuclear accumulation, CTCF threonine phosphorylation and its association with cohesin subunits.

This aberrant CTCF activation was observed not only in mice exposed to PM but also in those exposed to cigarette smoke, suggesting it’s a common pathway in COPD development, regardless of the source of exposure.⁴ Analysis of data from COPD patients further supports this finding, showing altered expression of genes regulated by CTCF in their alveolar macrophages.

Expert Insight: Identifying a common pathway like CTCF activation across different COPD triggers – particulate matter and cigarette smoke – is significant. It suggests that targeting this pathway could potentially offer a broader therapeutic approach, benefiting a wider range of patients.

A Promising New Compound: Gaylussacin

Researchers screened a variety of compounds to find those that could inhibit the effects of PM on macrophages. Gaylussacin, a stilbenoid, emerged as a strong candidate. It effectively suppressed CTCF activity and reduced oxidative stress in macrophages without causing toxicity to other cell types. Gaylussacin reduced PM-induced CTCF threonine phosphorylation and its association with cohesin subunits, as well as chromatin binding of the CTCF-cohesin complex.

Further investigation revealed that gaylussacin works by inhibiting CK2, thereby restoring normal gene expression and reducing inflammation. In laboratory tests, gaylussacin also showed promise in a mouse model of PM-induced COPD, reducing lung damage and inflammation. The compound is metabolized into pinosylvic acid, which also demonstrated efficacy in reducing COPD progression.

Frequently Asked Questions

What role do macrophages play in COPD?

Dysregulated macrophages drive COPD pathogenesis by inducing inflammation and tissue destruction through excessive secretion of cytokines, reactive oxygen and nitrogen species (ROS/RNS), and proteases.¹

What is the connection between CK2 and CTCF in COPD?

Researchers found that PM exposure increases CK2 activity, which then leads to increased CTCF phosphorylation and altered gene expression in macrophages, contributing to COPD development.

What are the next steps in researching gaylussacin as a potential COPD treatment?

Future studies investigating the role of CTCF in PM-induced COPD employing patient tissues with well-documented PM exposure, as well as clinical evaluation of the efficacy, pharmacokinetics, and safety of gaylussacin in COPD patients or high-risk populations, are warranted.

Given these findings, could targeting the CK2/CTCF pathway with compounds like gaylussacin represent a new avenue for treating COPD and improving the lives of those affected by this debilitating disease?